OncologyConsults



Appropriate Use of Immune Therapy to Treat Head and Neck Cancer

Presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.

Supported by an educational grant from Merck & Co, Inc.

OVERVIEW
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit. In this activity, we will review recent clinical advancements in treating and managing patients with metastatic head and neck squamous cell carcinoma with a particular focus on immunotherapeutic agents called immune checkpoint inhibitors. Appropriate care of a patient with human papilloma virus-associated oropharyngeal carcinoma will be delineated to illustrate some of the specific clinical issues that arise in managing patients with this type of cancer. The importance of p16 testing of oropharyngeal carcinoma, the concept of deintensification in this patient population, and the new list of oncologic agents available for patients with recurrent or metastatic cancers will be discussed. Lastly, the importance of multidisciplinary care in the management of these complex head and neck cancer patients will be highlighted.

GOAL
The goal of this activity is to provide oncology healthcare providers with current and relevant clinical information in the management of patients with advanced head and neck carcinoma.

TARGET AUDIENCE
This activity is designed for oncology healthcare providers (oncologists, oncology nurses, nurse practitioners, and oncology physician assistants) who care for patients with head and neck cancers. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  • SUMMARIZE the workup of patients with head and neck squamous cell carcinoma (HNSCC).
  • DISCUSS the use of molecular and histologic tumor testing and prior treatment history in selecting a treatment strategy.
  • DESCRIBE emerging immunotherapy agents for the treatment of recurrent or metastatic HNSCC.
The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

CE INFORMATION
Accreditation Statements — This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statements — The Johns Hopkins University School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category I Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This .5 contact hours of educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until September 7, 2018.

Release date: September 7, 2016    Expiration date: September 7, 2018

FACULTY
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation.

Policy on Faculty and Provider Disclosure
It is the policy of the Institute for Johns Hopkins Nursing to require our continuing nursing education faculty and planning committee members to disclose any financial relationships with companies providing program funding or manufacturers of any commercial products discussed in the educational activity.

The following relationships have been reported for this activity:

Chair and Planner
David S. Ettinger, MD

Alex Grass Professor in Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Nurse Planner
Rebecca Barshick, RN, MSN

Nurse Educator
The Institute for Johns Hopkins Nursing
Baltimore, Maryland

Participating Faculty
Young Jun Kim, MD, PhD

Associate Professor of Otolaryngology – Head and Neck Surgery
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Bloomberg-Kimmel Institute of Cancer Immunotherapy
Baltimore, Maryland

Nurse Reviewer
Carol Maragos, MSN, ACNP-BC, CORLN

Nurse Practitioner
Otolaryngology Head and Neck Surgery
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Bloomberg-Kimmel Institute of Cancer Immunotherapy
Baltimore, Maryland

Participating Faculty Disclosures
Dr Kim reports receiving grants/research support from Aduro Biotech.

Planner Disclosures
Dr Ettinger reports serving as a principal investigator for Golden Biotechnology Corp; serving on the data monitoring committee for ARIAD Pharmaceuticals Inc; and serving as a consultant for Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono Inc, and Genentech Inc, Helsinn Therapeutics, Inc.

Dr Kim reports receiving grants/research support from Aduro Biotech.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
No faculty member has indicated that their presentation will include information on off-label products.

Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

For CME questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu.
Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT
The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@.jhmi.edu.

ACTIVITY INSTRUCTIONS
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME/CNE post-test and evaluation. All 3 sections must be completed to receive CME/CNE credit. A certificate of participation will be available online immediately following successful completion of the activity.

Pre-Test

Appropriate Use of Immune Therapy to Treat Head and Neck Cancer

Young Jun Kim, MD, PhD

Post-Test

This activity was developed in collaboration with ASiM.


© 2017 - OncologyConsults.com